Acquisitions12 Oct 2026, 06:50 pm
Tavexia Lifecare Acquires Meyonex Pharma for ₹67.19 Crore
AI Summary
Tavexia Lifecare Limited announced a strategic expansion with the acquisition of a 60% stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore. The acquisition, priced at ₹32 per share through fresh equity, will be executed via cash subscription. This move provides Tavexia with an immediate operational base in Maharashtra and broadens its business into high-margin verticals such as APIs, finished dosage forms, CDMO/CRAMS, nutraceuticals, and biotechnology. The company plans strategic fund-raising to support this growth roadmap, aiming to leverage sector tailwinds like domestic manufacturing support and global supply-chain diversification.
Key Highlights
- Acquisition of 60% stake in Meyonex Pharmaceuticals for ₹67.19 Crore.
- Expansion into high-growth verticals: APIs, formulations, CDMO, nutraceuticals.
- Acquisition provides immediate manufacturing and commercial operations.
- Plans for strategic fund-raising to support growth initiatives.
- Positioning to benefit from 'China+1' strategies and domestic manufacturing support.
Price Impact
More from SATTVASUKU